Quick Comparison
| CDP-Choline | Citicoline (CDP-Choline) | |
|---|---|---|
| Half-Life | 56-71 hours (long elimination half-life) | 56-71 hours (sustained release characteristics) |
| Typical Dosage | Standard: 250-500 mg daily in 1-2 doses. Clinical (stroke/cognitive decline): 500-2000 mg daily. Most nootropic users find 250-500 mg sufficient. | Standard: 250-500 mg daily. Clinical studies use 500-2000 mg daily. Take in the morning — mildly stimulating. Cognizin is the most studied form. Can be split into 2 doses. Often combined with racetams to provide the choline needed for enhanced acetylcholine turnover. |
| Administration | Oral (capsules, tablets). Very well-absorbed with nearly 100% oral bioavailability. | Oral (capsules, powder). Cognizin branded form is most studied. Take in the morning. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
CDP-Choline
CDP-Choline is hydrolyzed by nucleotidases and phosphatases into choline and cytidine after oral ingestion. Choline enters the acetylcholine synthesis pathway via choline acetyltransferase. Cytidine is phosphorylated to CTP and converted to uridine monophosphate (UMP), which enters the Kennedy pathway and stimulates the synthesis of phosphatidylcholine via the enzyme CTP:phosphocholine cytidylyltransferase — phosphatidylcholine is a critical component of neuronal cell membranes and synaptic vesicles. This dual mechanism simultaneously boosts neurotransmitter production and repairs membrane damage from oxidative stress or ischemia. CDP-Choline also increases dopamine D2 receptor density in the striatum and enhances dopamine release. It may modulate glutamate excitotoxicity and support mitochondrial function.
Citicoline (CDP-Choline)
Citicoline (CDP-choline) is hydrolyzed in the gut by alkaline phosphatase to choline and cytidine-5'-monophosphate, which are absorbed separately and reassembled in the brain via the Kennedy pathway. Choline feeds two critical pathways: (1) Acetylcholine synthesis via choline acetyltransferase (ChAT) — the primary memory and learning neurotransmitter acting at muscarinic and nicotinic receptors. (2) Phosphatidylcholine synthesis via CTP:phosphocholine cytidylyltransferase — the structural component of neuronal membranes and synaptic vesicles. Cytidine is dephosphorylated to uridine, converted to UTP, and supports RNA synthesis and CDP-choline formation for synapse formation. Citicoline also activates SIRT1 (possibly via NAD+ modulation) and increases brain norepinephrine and dopamine (mechanism unclear — may enhance synthesis or release). It is the only choline source providing both cholinergic and membrane-building support in one molecule.
Risks & Safety
CDP-Choline
Common
Headache, nausea, diarrhea, insomnia.
Serious
Very safe — extensive clinical safety data.
Rare
Blurred vision, chest pain, allergic reactions.
Citicoline (CDP-Choline)
Common
Headache (especially with racetams — indicates too much cholinergic stimulation), nausea, diarrhea.
Serious
None documented at standard doses.
Rare
Insomnia, blurred vision.
Full Profiles
CDP-Choline →
Also known as Citicoline, this is a naturally occurring compound that provides both choline and cytidine (which converts to uridine in the body). This dual action supports both acetylcholine synthesis and cell membrane repair, making it both a cognitive enhancer and a neuroprotectant. Prescribed in many countries for stroke recovery and cognitive decline.
Citicoline (CDP-Choline) →
A naturally occurring intermediate in the synthesis of phosphatidylcholine, the primary phospholipid in neuronal cell membranes. Citicoline provides both choline (for acetylcholine and phospholipid synthesis) and cytidine (converted to uridine, supporting RNA and synapse formation). It is prescribed in Europe and Japan for stroke recovery and cognitive decline. Cognizin is the most studied branded form.